Neuropathic pain affects more than 20 million people in the U.S., and at least a quarter of these cases are puzzling for ...

The Phase III trial AV001 aims to evaluate QUTENZA® in post- surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after ...

Objective: To assess the efficacy, safety and impact on quality of life of tramadol in the treatment of neuropathic pain in patients with cancer. Methods: Patients with similar characteristics ...

Researchers at Weill Cornell Medicine and the Burke Neurological Institute have made an exciting discovery—a new drug that ...

The FDA has placed a trial of Rapport Therapeutics’ epilepsy drug for a type of nerve pain on hold while the biotech tweaks ...

Long-term, low-dose antiviral treatment reduces the risk for potentially ... ligands on murine neuropathic pain models, their effects on nociceptive neurons and the mechanism of action after ...

Fewer Cognitive Side Effects: With the potential to avoid sedation and cognitive impairment, Ketamir-2 offers an improved ...

Neuropathic pain is a chronic and debilitating condition that impacts around 10% of the population in both the United States and Europe. Despite advances in understanding the mechanisms of neuropathic ...

Ketamir-2, a non-opioid, offers tremendous promise for patients seeking better solutions for neuropathic pain without the ... promising alternative to current treatments. Ketamir-2 offers several ...

Recent evidence suggests that acupuncture can help relieve the pain caused by sciatica, a common condition in which the ...

European researchers have mapped the most comprehensive phenotyping of neuropathic pain and identified genetic markers associated with this serious condition.

FREEHOLD, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced the ...